DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and
builds out Senior Management Team with standout industry professionals in
the US
2020-12-17 / 09:00
The issuer is solely responsible for the content of this announcement.
*Immune Regulation appoints New Chairman and builds out Senior Management
Team with standout industry professionals in the US*
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US
and UK based clinical stage biotechnology company announced today a series
of appointments to build out the Board and leadership team that will work
alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the
development of its first-in-class immune resetting therapies for autoimmune
and allergic diseases.
Veteran biotech executive *Peter Greenleaf* has been appointed _Chairman of
the Board of Directors_. Peter currently serves as the CEO and member of the
Board of Directors of autoimmune therapeutics company Aurinia, (NASDAQ; AUPH
/ TSX; AUP). Previously, Peter served as the CEO of Cerecor Inc. (Nasdaq;
CERC), the CEO and Chairman of Sucampo Pharmaceuticals Inc. (NASDAQ; SCMP),
CEO and a member of the Board of Directors of Histogenics Corporation,
President of Medlmmune LLC and Medlmmune Ventures. He is also currently a
member of the Board of Directors of Antares Pharmaceuticals Inc. (NASDAQ;
ATRS) and Chairman of Biodelivery Sciences International, Inc (NASDAQ;
BDSI).
*Jones W. (Woody) Bryan Ph.D, Perry Calias Ph.D, Jeff Myers M.D., Marylyn
Rigby* and *Nancy Vinh* have also joined Immune Regulation's leadership
team.
Woody has been appointed _Chief Business Officer_ and is a highly
experienced and well-regarded business operations professional with a very
successful track record in the healthcare industry. Most recently he served
as SVP of Business Development at UroGen Pharmaceuticals Inc., (Nasdaq;
URGN) and as SVP of Business Development at Sucampo Pharmaceuticals Inc.
(Nasdaq; SCMP), where he spearheaded the effort for its acquisition by
Mallinckrodt Pharmaceuticals for $1.2 billion. His previous experience
includes SVP of BD at Lupin Pharmaceuticals Inc., VP of BD and Licensing at
Supernus Pharmaceuticals, (Nasdaq; SUPN), VP BD, Licensing and Project
Management at Shire Laboratories and led scientific and BD leadership
positions at AAI and Schering Plough.
Perry has been appointed _Chief Operating Officer _andbrings over 25 years
of biopharmaceutical experience in clinical development across the drug and
device sectors of healthcare. He has a strong track record in compound
development, drug delivery and pipeline progression, as well as building R&D
organizations. His previous experience includes serving as Chief Scientific
Officer and Head of R&D at Cerecor Inc. (Nasdaq; CERC) and Vice President of
Global CMC and Product Development at Sucampo Pharmaceuticals (Nasdaq;
SCMP). He has also held a variety of R&D positions both in clinical and
non-clinical roles of expanded leadership at Shire HGT and Genzyme.
Jeff has been appointed _Chief Medical Officer_ and is an experienced
biotech executive with experience in all phases of drug development from
pre-clinical through to commercial. Most recently, Jeff served as the SVP of
Global Medical Affairs and Interim CMO at Portola Pharmaceuticals (Nasdaq;
PTLA) through the eventual acquisition by Alexion. While at Gilead (Nasdaq;
GILD) he was the Global Medical Affairs Lead for the CV franchise including
pulmonary hypertension, chronic angina, and cystic fibrosis. At SteadyMed
Therapeutics (Nasdaq; STDY) he led the clinical and regulatory programs
prior to the acquisition by United Therapeutics (Nasdaq; UTHR). Most
recently, Jeff served as the SVP of Global Medical Affairs and Interim CMO
at Portola Pharmaceuticals (Nasdaq; PTLA) through the eventual acquisition
by Alexion. He served as the Chief of Paediatric Cardiac Surgery at The
Massachusetts General Hospital and Associate Professor for Surgery at
Harvard Medical School prior to beginning his career in industry.
Marylyn has been appointed _VP of Marketing and Investor Relations_ and is a
results driven, experienced pharmaceutical, biotech and drug delivery
professional. In addition to her expertise in marketing, public and investor
relations, she has a successful track record with BD, licensing, public and
private equity financing, strategy and other key corporate functions.
Previously she led the marketing and patient outreach programs for a lead
development stage product to treat Pulmonary Arterial Hypertension (PAH) at
United Therapeutics (Nasdaq; UTHR). As the head of Marketing and Investor
Relations at SteadyMed Therapeutics Inc, (Nasdaq; STDY) she assisted the
company through multiple private equity financings a Nasdaq listing in 2015
and a public-to-public company sale to United Therapeutics (Nasdaq; UTHR) in
2018. Earlier in her career Marylyn was the lead licensing professional at
Cydex Pharmaceuticals prior to its acquisition by Ligand Pharmaceuticals
(Nasdaq; LGND).
Nancy has been appointed as _VP Clinical Operations_ and has over twenty
years of experience managing early and late phase, international clinical
trials for drugs, biologics, cell therapy and combination products across a
wide range of therapeutic areas. Formerly she was Head of Clinical
Operations at Portola Pharmaceuticals (Nasdaq; PTLA) where she was
responsible for the development of clinical trial operations, strategy and
trial execution for a number of therapeutics. Earlier she headed up Clinical
Operations at Cellerant Therapeutics, and Nile Therapeutics and led
registrational and label expansion trials execution at CV Therapeutics.
Commenting on the appointments, Group CEO Jonathan Rigby said, "I am
thrilled that the promise of our pipeline of revolutionary autoimmune and
allergic disease products and our culture of drive and commitment has
allowed me to attract such incredible professionals in the US to complement
our UK based team."
Commenting on his new role, Chairman of the Board of Directors Peter
Greenleaf said, "I have led a number of very successful companies over the
years and it is clear that Immune Regulation has built a world class team to
execute on its clinical development goals in multiple autoimmune and
allergic diseases. I look forward to working with the team to help them
achieve their goals."
*For further enquiries*
Immune Regulation Ltd
Jonathan Rigby, Group CEO
+1 510 589 3268
jonathan.rigby@immuneregulation.com
www.immuneregulation.com [1]
*About Immune Regulation *
Immune Regulation Limited is a US and UK based clinical stage biotechnology
company, pioneering new technologies for regulating and resetting the immune
system and developing novel first-in-class therapies for inflammatory and
immunological diseases.
Immune Regulation's first-in-class immune resetting therapies have
demonstrated unique efficacy and safety in pre-clinical and human studies
without suppressing the immune system.
*Forward-Looking Statements*
This announcement includes forward-looking statements, being statements made
in the announcement that are not historical fact. Forward-looking statements
can generally be identified by the use of words including "anticipate",
"may", "believe", "estimate", "intend", "expect" and words of similar
meaning. Such forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause the Company's
actual results, performance or achievements to be materially different from
the results, performance or achievements contemplated by the forward-looking
statements in this announcement. The forward-looking statements speak only
to the date of this announcement. Neither the Company, nor any shareholder,
affiliate, employee, adviser or representative of the Company shall be under
any obligation to, and all of those persons expressly disclaim any
obligation to, update or revise the forward-looking statements contained in
this announcement.
2020-12-17 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
1155802 2020-12-17
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=45ff0074f3575a1a164c7b7bd35e7c30&application_id=1155802&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 17, 2020 03:00 ET (08:00 GMT)